A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

  1. Climent, M.A.
  2. Font, A.
  3. Durán, I.
  4. Puente, J.
  5. José Méndez-Vidal, M.
  6. Sáez, M.I.
  7. Santander Lobera, C.
  8. Ángel Arranz Arija, J.
  9. González-del-Alba, A.
  10. Sánchez-Hernandez, A.
  11. Juan Fita, M.J.
  12. Esteban, E.
  13. Alonso-Gordoa, T.
  14. Mellado Gonzalez, B.
  15. Maroto, P.
  16. Lázaro-Quintela, M.
  17. Cassinello-Espinosa, J.
  18. Pérez-Valderrama, B.
  19. Garcias, C.
  20. Castellano, D.
Journal:
European Journal of Cancer

ISSN: 1879-0852 0959-8049

Year of publication: 2022

Volume: 175

Pages: 110-119

Type: Article

DOI: 10.1016/J.EJCA.2022.08.002 GOOGLE SCHOLAR

Sustainable development goals